Pubblicazioni

LifeVest è stato al centro di più di 100 pubblicazioni scientifiche e presentazioni negli ultimi anni.

Qui potrete trovare alcune delle pubblicazioni su LifeVest

  1. Bossory L, Patel D, Godara H, Badin A, Afzal M, Weiss R, Tyler J, Kalbfleisch SJ, Daoud EG, Liu Z, Augostini RS, Hummel J, Okabe T, Houmsse M. Real world clinical experience with wearable cardioverter defibrillators at a large electrophysiology program. 2017 May Supplement;44(5):S253.

  2. Saouma S, Samaha G, Karam B, Raza M, Willner J, Akhrass P, Kowalski M, Bekheit S. Epstein-Barr virus induced fatal ventricular arrhythmia. 2017 May Supplement;44(5):S299.

  3. Spar D, Knilans TK, Czosek RJ, Bianco NR, Anderson JB. The US experience of the wearable cardioverter defibrillator in pediatric patients. 2017 May Supplement;44(5):S46.

  4. Daimee U, Vermilye K, Moss AJ, Goldenberg I, Klein HU, McNitt S, Zareba W, Kutyifa V. Experience with the wearable cardioverter defibrillator in older patients: results from the WEARIT-II registry. Heart Rhythm. 2017 May Supplement;44(5):S130.

  5. Scherr D, Odeneg T, Ebner C, Moertl D, Keller H, Stuehlinger MC, Steinwender C, Stix G, Fiedler LM, Manninger M. Indications for and outcome in patients with the wearable cardioverter defibrillator (WCD) – the Austrian WCD Registry. Heart Rhythm. 2017 May Supplement;44(5):S127.

  6. de Groot JR. The wearable defibrillator: a most affordable vest. Neth Heart J. 2017 May;25(5):293-294.

  7. Quast AFBE, van Dijk VF, Wilde AAM, Knops RE, Boersma LVA. Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres. Neth Heart J. 2017 May;25(5):312-317.

  8. Beiert T, Malotki R, Kraemer N, Stöckigt F, Linhart M, Nickenig G, Schrickel JW, Andrié RP. A real world wearable cardioverter defibrillator experience - Very high appropriate shock rate in ischemic cardiomyopathy patients at a European single-center. J Electrocardiol. 2017 Apr 28. pii: S0022-0736(17)30120-6. doi: 10.1016/j.jelectrocard.2017.04.017. [Epub ahead of print]

  9. Wan C, Szymkiewicz SJ, Klein HU. The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time. Am Heart J. 2017 Apr;186:111-117.

  10. Barsheshet A, Kutyifa V, Vamvouris T, Moss AJ, Biton Y, Chen L, Storozynsky E, Wan C, Szymkiewicz SJ, Goldenberg I. Study of the wearable cardioverter defibrillator in advanced heart-failure patients (SWIFT). J Cardiovasc Electrophysiol. 2017 Apr 21. doi: 10.1111/jce.13229. [Epub ahead of print]

  11. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas C, Pfister R, Thomas D, Fürnkranz A, Andrié R, Napp A, Schmitt J, Karolyi L, Wakili R, HilfikerKleiner D, Bauersachs J, Veltmann CG. Elevated risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy – Data from a German multicenter study. Presented at DGK Spring 2017.

  12. Erath JW, Vamos M, Benz A, Steidl A, Hohnloser S. Protecting Tachy[cardio]myopathy Patients with the Wearable Cardioverter Defibrillator. Presented at DGK Spring 2017.

  13. Schuhmann CG, Kubieniec M, Lackermair K, Kääb S, Wakili R, Estner HL, Fichtner S. Real life experience with the treatment period (wear time) of the wearable cardioverter defibrillator (WCD) and followup including quality of life from a German single center cohort. Presented at DGK Spring 2017.

  14. Beiert T, Malotki R, Kraemer N, Stöckigt F, Linhart M, Nickenig G, Schrickel1 JW, Andrié R. A Real World Wearable Cardioverter Defibrillator Experience – what are the relevant indications? Presented at DGK Spring 2017.

  15. K. Krause1, D. Stierle1, A. Khan1, H. Nägele1. Wearable defibrillator in newly diagnosed heart failure: reduced rate of ICD implantation after improvement of left ventricular ejection fraction. Presented at DGK Spring 2017.

  16. Johnson V, Grieshaber P, Lehnhardt S, Böning A, Hamm CW, Schmitt J. Effectiveness of wearable cardioverter defibrillators in ischemic cardiomyopathy: Comparison of revascularization procedures (PCI vs. CABG). Presented at DGK Spring 2017.

  17. Kaspar G, Sanam K, Gholkar G, Bianco NR, Szymkiewicz SJ, Shah D. Long-Term Use of the Wearable Cardioverter Defibrillator in ICD Explant Patients. Presented at ACC 2017.

  18. Erath JW, Vamos M, Sirat AS, Hohnloser SH. The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients. Clin Res Cardiol. 2017 Apr;106(4):300-306.

  19. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study. Clin Cardiol. 2017 Mar 23. doi: 10.1002/clc.22706. [Epub ahead of print]

  20. Schmitt J, Abaci G, Johnson V, Erkapic D, Gemein C, Chasan R, Weipert K, Hamm CW, Klein HU. Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers. Pacing Clin Electrophysiol. 2017 Mar;40(3):271-277.

  21. Andrié R, Gaertner FC, Skowasch D. Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis. Thorax. 2017 Mar;72(3):286-287.

  22. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R, Thomas D, Fürnkranz A, Andrié RP, Napp A, Schmitt J, Karolyi L, Wakili R, Hilfiker-Kleiner D, Bauersachs J, Veltmann C. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol. 2017 Mar 8. doi: 10.1007/s00392-017-1090-5. [Epub ahead of print]

  23. Reek S, Burri H, Roberts PR, Perings C, Epstein AE, Klein HU. The wearable cardioverter-defibrillator: current technology and evolving indications. Europace. 2017 Mar 1;19(3):335-345.

  24. Sharma PS, Bordachar P, Ellenbogen KA. Indications and use of the wearable cardiac defibrillator. Eur Heart J. 2017 Jan 21;38(4):258-267.

  25. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. J Am Heart Assoc. 2017 Jan 17;6(1).

  26. Lamichhane M, Gardiner JC, Bianco NR, Szymkiewicz SJ, Thakur RK. National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy. J Interv Card Electrophysiol. 2017 Jan;48(1):11-19.

  27. Reek S. The wearable defibrillator: current technology, indications and future directions. Curr Opin Cardiol. 2017 Jan;32(1):39-46.

  28. Sasaki S, Shoji Y, Ishida Y, Kinjo T, Tsushima Y, Seno M, Nishizaki F, Itoh T, Izumiyama K, Yokota T, Yokoyama H, Yamada M, Horiuchi D, Kimura M, Higuma T, Tomita H, Okumura K. Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience. J Cardiol. 2017 Jan;69(1):359-363.

  29. Ferrick AM, Tian D, Vudathaneni V, Shevchuk OL, Ferrick NJ, Frishman W. Wearable Cardioverter Defibrillators. Cardiol Rev. 2016 Nov/Dec;24(6):282-287.

  30. Reuschel E, Baessler A, Stöllberger C, Finsterer J, Maier L, Fischer M, Poschenrieder F, Heissenhuber F, Kurzidim K, Schepp CP, Badelt G, Seelbach-Göbel B. Interdisciplinary management of left ventricular hypertrabeculation/noncompaction during pregnancy with a wearable defibrillator. Int J Cardiol. 2016 Nov 15;223:154-158.

  31. Kondo Y, Ueda M, Kobayashi Y. Efficacy and Cost-Effectiveness of Wearable Cardioverter Defibrillator as a Lifesaving-Bridge Therapy for Decision in High Risk Patients of Sudden Arrhythmic Death : 3-Year Follow-Up Result. Circulation. 2016;134:A20724.

  32. Wan C, Szymkiewicz S. Outcome of In-Hospital VT/VF Arrest by Time and Location When Using a Wearable Cardioverter Defibrillator. Circulation. 2016;134:A19507.

  33. Waessnig NK, Guenther M, Quick SQ, Pfluecke C, Rottsaedt RH, Ringquist SM, Szymkiewicz SJ, Strasser RH. Safety of physician-initiated programming of wearable cardioverter-defibrillator detection rates. Eur Heart J (2016) 37 (suppl_1): 217.

  34. Odeneg T, Manninger Wuenscher M, Ebner CE, Moertl DM, Keller HK, Brussee HB, Scherr DS. The use of the wearable cardioverter defibrillator in Austria. Results of the Austrian LifeVest Registry. Eur Heart J (2016) 37 (suppl_1): 396.

  35. Stiermaier T, Rommel KP, Eitel C, Möller C, Graf T, Desch S, Thiele H, Eitel I. Management of arrhythmias in patients with Takotsubo cardiomyopathy: Is the implantation of permanent devices necessary? Heart Rhythm. 2016 Oct;13(10):1979-86.

  36. Eckardt L, Deneke T. [Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death]. Herzschrittmacherther Elektrophysiol. 2016 Sep;27(3):288-94.

  37. Kondo Y, Ueda M, Kobayashi Y, Schwab JO. New horizon for infection prevention technology and implantable device. J Arrhythm. 2016 Aug;32(4):297-302.

  38. Nishii N. Arrhythmia management after device removal. J Arrhythm. 2016 Aug;32(4):287-92.

  39. Lamichhane M, Safadi A, Surapaneni P, Salehi N, Thakur RK. Use of the Wearable Cardioverter Defibrillator in High-Risk Populations. Curr Cardiol Rep. 2016 Aug;18(8):78.

  40. Kandzari DE, Perumal R, Bhatt DL. Frequency and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction. Clin Cardiol. 2016 Jul;39(7):399-405.

  41. Barsheshet A, Vamvouris T, Goldenberg I. The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know? Expert Rev Med Devices. 2016 Jul;13(7):627-32.

  42. Wäßnig NK, Günther M, Quick S, Pfluecke C, Rottstädt F, Szymkiewicz SJ, Ringquist S, Strasser RH, Speiser U. Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. Circulation. 2016 Aug 30;134(9):635-43.

  43. Kutyifa V, Moss AJ, Klein H, Biton Y, Mcnitt S, Goldenberg I. One-Year Follow-Up of the Prospective Registry of Patients Using The Wearable Defibrillator (WEARIT-II Registry). Europace (2016) 18 (suppl_1): i113.

  44. Reif S, Krieg HJ, Dorwarth U, Hoffmann E. Do Airport Handheld Metal Detectors Interact with Wearable Cardioverter Defibrillators? Europace (2016) 18 (suppl_1): i129.

  45. Odeneg T, Ebner C, Keller H, Moertl D, Manninger M, Scherr D. Indications for the use of the wearable cardioverter defibrillator – the Austrian LifeVest Registry. Europace (2016) 18 (suppl_1): i129.

  46. Duncker D, Hohmann S, König T, Zauner F, Kattih B, Löffler F, Pfeffer T, Oswald H, Veltmann C. Long-term “real-life” high-volume wearable cardioverter/defibrillator program – Single centre experience of 255 patients covering more than 50 patient-years. Europace (2016) 18 (suppl_1): i128.

  47. Sasaki S, Shoji Y, Ishida Y, Kinjo T, Tsushima Y, Nishizaki K, Daisuke H, Kimura M, Okumura K. Usefulness and potential role of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience. Europace (2016) 18 (suppl_1): i128.

  48. Kutyifa V, Bianco NR, Szymkiewicz SJ, Moss AJ, Chen L. First Clinical Experience with the Wearable Cardioverter Defibrillator in Left Ventricular Assist Device Patients. Europace (2016) 18 (suppl_1): i128.

  49. Barsheshet A, Kutyifa V, Vamvouris T, Moss AJ, Biton Y, Chen L, Storozynsky E, Wan C, Szymkiewicz SJ, Goldenberg I. Study of the Wearable Cardioverter Defibrillator in Advanced Heart-Failure Patients (SWIFT). Heart Rhythm. 2016;13(5):S19.

  50. Scherr D, Haider C, Manninger-Wuenscher M, Ebner J, Bisping E, Lercher P, Prenner G, Rotman B, Stiegler P, Brussee H, Odeneg T. Indications for and Outcome in Patients with the Wearable Cardioverter Defibrillator (WCD) – Results of the Austrian WCD Registry. Heart Rhythm. 2016;13(5):S357.

  51. Kondo Y, Kurita T, Ueda M, Miyazawa K, Ishimura M, Nakano M, Kobayashi Y. Efficacy and cost-effectiveness of wearable cardioverter defibrillator as a lifesaving bridge therapy for decision in high risk Japanese patients of sudden arrhythmic death. Heart Rhythm. 2016;13(5):S150.

  52. Perumal R, Szymkiewicz S. Higher incidence of ventricular fibrillation in nonischemic cardiomyopathy patients does not affect survival when using the wearable cardioverter defibrillator. Heart Rhythm. 2016;13(5):S109.

  53. Johnson VL, Erkapic D, Weipert KF, Gemein C, Chasan R, Hamm CW, Schmitt J. Accurate detection of VT and VF by the wearable cardioverter defibrillator during simultaneous uni- and bi-polar ventricular stimulation. Heart Rhythm. 2016;13(5):S522.

  54. Naniwadekar A, Joshi KR, Oasare ER, Alnabelksi T, Melendres E, Malik M, Greenspan A, Mainigi S. Real world utilization and impact of the wearable defibrillator in a community setting. Heart Rhythm. 2016;13(5):S525.

  55. Bianco NR, Szymkiewicz SJ. Outcomes After Asystole Events During Wearable Cardioverter Defibrillator Use. Heart Rhythm. 2016;13(5):S522.

  56. Hain A, Neumann T, Kuniss M, Hamm CW, Sperzel J. Die Defibrillatorweste als transienter Schutz vor dem plötzlichen Herztod und Diagnostiktool bei der Detektion von klinisch relevanten HRST. Presented at DGK Spring 2016 [in German].

  57. Konrad T, Sonnenschein S, Schulz E, Wenzel P, Wagner S, Schmidt KH, Münzel T, Theis C, Rostock T, Mollnau H. What is the incidence of ventricular arrhythmias in the mid-term phase of acute myocarditis? New insights from the Wearable Cardioverter / Defibrillator. Presented at DGK Spring 2016.

  58. Odeneg T, Manninger-Wünscher CHM, Ebner J, Bisping E, Lercher P, Prenner G, Rotman B, Stiegler P, Brussee H, Scherr D. Indikationen für und Erfahrungen mit dem Gebrauch eines tragbaren Kardioverter‑Defibrillators bei Patienten mit hohem Risiko für plötzlichen Herztod – erste Daten des Österreichregisters. Presented at DGK Spring 2016 [in German].

  59. Duncker D, Veltmann C. The Wearable Cardioverter/Defibrillator - Toy Or Tool? J Atr Fibrillation. 2016 Apr 30;8(6):1367

  60. Piccini et al. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. Circulation. 2016 Mar 28. [Epub ahead of print].

  61. Doz P, Sperzel J. Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD). J Atr Fibrillation. 2016 Feb 29;8(5):1247.

  62. Kishihara et al. An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting. J Arrhythm. 2016 Feb;32(1):67-9.

  63. Biton et al., “Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure,” Heart Fail Rev. 2016 Feb 24. [Epub ahead of print].

  64. Simpson. Gimmick or Godsend? The Wearable Cardioverter Defibrillator (WCD). Can J Cardiol. 2016 Feb 12. [Epub ahead of print].

  65. Salehi et al. The Wearable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A US National Database Analysis. Can J Cardiol. 2016 Jan 14. [Epub ahead of print].

  66. Luo et al. Wearable Automatic External Defibrillators. Zhongguo Yi Liao Qi Xie Za Zhi. 2015 Nov;39(6):391-4. [Article in Chinese].

  67. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1;36(41):2793-867.

  68. Kondo et al., “Usefulness of the wearable cardioverter defibrillator in patients in the early post-myocardial infarction phase with high risk of sudden cardiac death: a single-center European experience,” J Arrhythm, 2015; (5):293-3.

  69. Wan et al., “Use of a Wearable Cardioverter Defibrillator (WCD) to protect patients after ICD explantation: results from the national registry,” Circulation, 2015; 132: A17589.

  70. Bianco et al., “The effect of internal vs. external shocks on myocardial injury in an animal model of myocardial infarction,” Circulation, 2015; 132:A19747.

  71. Bianco et al., “Successful reversed polarity defibrillation with the Wearable Cardioverter Defibrillator,” Circulation, 2015; 132: A19492.

  72. Ringquist et al., “Conversion of recurrent arrhythmia by the Wearable Cardioverter-Defibrillator,” Circulation, 2015; 132: A17241.

  73. Luo et al. Wearable Automatic External Defibrillators. Zhongguo Yi Liao Qi Xie Za Zhi. 2015 Nov;39(6):391-4. [Article in Chinese].

  74. Kutyifa V, Moss AJ, Klein H, et al. Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients: Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015; 132(17): 1613-1619.

  75. Yoshikawa et al., “Usefulness of a wearable cardioverter defibrillator combined with catheter ablation for ventricular tachyarrhythmia storms after a myocardial infarction: A case report,” J Arrhythm, 2015; 31(4):257-60.

  76. Horlbeck et al., “A 65-year-old man with wearable cardioverter/defibrillator early after acute myocardial infarction,” Internist, 2015; 56(9):1062-8 [in German].

  77. Waessnig et al., “German national experience with the wearable cardioverter defibrillator,” Eur Heart J, 2015; 36(suppl 1):192.

  78. Johnson et al., “Arrhythmia treatment and survival of patients wearing the cardioverter defibrillator vest,” Eur Heart J, 2015; 36(suppl 1):1032.

  79. Estes, “Making a case for the wearable cardioverter defibrillator,” Nursing, 2015; 45(7):66.

  80. Duncker, “Quality of life, biomarkers and ICD indications in patients with a wearable cardioverter/defibrillator - preliminary results of a prospective trial with 1 year of follow-up,” Europace, 2015; 17 (suppl 3): iii147.

  81. Sinha et al., “Wearable cardioverter defibrillator reduces implantation rate of ICD in patients with high risk for life-threatening cardiac arrhythmias,” Europace, 2015; 17 (suppl 3): iii148.

  82. Permual et al., “Ischemia prior to ventricular tachyarrhythmia does not affect survival in acute myocardial infarction patients treated with a wearable cardioverter defibrillator,” Europace, 2015; 17 (suppl 3): iii237-iii259.

  83. Fan et al., “Key clinical features a general internist needs to know about Brugada syndrome: a case-based discussion,” J Community Hosp Intern Med Perspect, 2015; 5(3):27241.

  84. Honigberg et al., “Arrhythmias in Peripartum Cardiomyopathy,” Card Electrophysiol Clin, 2015; 7(2):309-317.

  85. Wan et al., “One-year Outcome for Medicare Beneficiaries with AMI using a Wearable Cardioverter Defibrillator,” Heart Rhythm, 2015; 12(5 suppl):S425.

  86. Santangeli et al., “Usage of a wearable cardioverter defibrillator in patients with advanced heart failure,” Heart Rhythm, 2015; 12(5 suppl):S418.

  87. Duncker et al., “Underestimated risk for life-threatening ventricular arrhythmias in newly diagnosed peripartum cardiomyopathy – a multicenter experience,” Heart Rhythm, 2015; 12(5 suppl):S131.

  88. Helms et al., “The Wearable Cardioverter-Defibrillator (WCD),” Herzschrittmacherther Elektrophysiol, 2015; 26(2):129-33. [in German]

  89. Opreanu et al., “Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis,” J Heart Lung Transplant, 2015; May 4. [Epub ahead of print].

  90. Mitrani et al., “Ten advances defining sudden cardiac death,” Trends Cardiovasc Med, 2015; Apr 4. [Epub ahead of print].

  91. Duncker et al., “Wearable cardioverter/defibrillator in peripartum cardiomyopathy early after diagnosis - a multicenter study,” Presented at DGK Spring 2015 [in German].

  92. Johnson et al. “Arrhythmia treatment and survival of Patients wearing the LifeVest,” Presented at DGK Spring 2015 [in German].

  93. Schmitt et al. “ICD-implantation, ICD-treatment and general survival of patients after returning the LifeVest,” Presented at DGK Spring 2015 [in German].

  94. Lang et al. “Wearable Cardioverter/Defibrillator (WCD) zur Risikostratifizierung und Überbrückung transienter Phasen mit einem hohen Risiko für den plötzlichen Herztod,”

  95. Sanders et al., “Potential Cost-effectiveness of Wearable Cardioverter Defibrillator Early Post Myocardial Infarction,” J Innovations in Cardiac Rhythm Management, 2015; 6(2015): 1929-1940.

  96. Healy et al., “Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death Following Infected Implantable Cardioverter Defibrillator Removal: A Cost-Effectiveness Evaluation,” Heart Rhythm. 2015; Mar 31. [Epub ahead of print].

  97. Huang et al., “Wearable cardioverter-defibrillator use in patients after myocardial infarction,” Zhonghua Xin Xue Guan Bing Za Zhi. 2014; 42(8):703-5. In Chinese.

  98. Duncker et al, “Risk for Ventricular Fibrillation in Peripartum Cardiomyopathy with Severely Reduced Left Ventricular Function – Value of the Wearable Cardioverter Defibrillator,” Eur J Heart Fail, 2014. 16(12):1331-6.

  99. Sasaki, et al. “Usefulness of the WCD in Patients at High Risk for Sudden Cardiac Death,” Circulation, 2014. 78(12):2987-9.

  100. Perumal, et al. “WCD Treatment Characteristics and Outcomes in Recent Myocardial Infarction Patients with Heart Failure,” Circulation, 2014; 130:A16255

  101. Wan, et al. “Left Ventricular Function Improvement After Recent MI in Patients Using a Wearable Cardioverter Defibrillator,” Circulation, 2014; 130:118973

  102. Bianco, et al. “Life-Threatening Arrhythmias During Wearable Cardioverter Defibrillator Use” Circulation, 2014; 130:A16751

  103. Wan, et al. “The Wearable Cardioverter Defibrillator Protects Older Patients from Sudden Cardiac Death” Circulation, 2014; 130:A341

  104. Chung MK, “The role of the wearable cardioverter defibrillator in clinical practice,” Cardiol Clin, 2014 May;32(2):253-70.

  105. Tanawuttiwat et al., “Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator,” PACE, 2014 May;37(5):562-8.

  106. Fan et al., “Application of ICD guidelines and indications in a community-based academic hospital: a case series-based discussion,” J Community Hosp Intern Med Perspect, 2014 Apr 14;4.

  107. Owen et al., “Personal Wearable Defibrillators for adults with long QT syndrome,” Heart Rhythm, 2014; 11(5):S52-S53.

  108. Duncker et al., “Risk of ventricular fibrillation in young mothers with peripartum cardiomyopathy,” Heart Rhythm, 2014; 11(5):S391.

  109. Bianco et al., “Wearable Cardioverter Defibrillator Use for Short-Term SCA Protection in Patients with Preserved LVEF Heart Failure,” Eur J Heart Fail, 2014; 16(s2):51.

  110. Wan et al., “Use of the Wearable Cardioverter Defibrillator in Patients with Infiltrative Disorders,” Eur J Heart Fail, 2014; 16(s2):314.

  111. Sinha et al., “Wearable Cardioverter Defibrillator in Patients with High Risk for Life-Threatening Cardiac Arrhythmias,” Europace, 2014; 16(suppl 2):ii96.

  112. Bianco et al., “Long-Term Use of the Wearable Cardioverter Defibrillator in ICD Explant Patients,” Europace, 2014; 16(suppl 2):ii97.

  113. Mijic et al., “The Wearable Cardioverter Defibrillator (WCD): A Sparkling Light in the Temporary Black Box before ICD Implantation,” Europace, 2014; 16(suppl 2):ii97.

  114. Permual et al., “Circadian variation of ventricular arrhythmias does not affect survival in patients using the wearable cardioverter defibrillator,” Euro Heart J, 2014; 35 (suppl 1):530.

  115. Wan et al., “Bridging to Recovery: Experience with the Wearable Cardioverter Defibrillator in Patients with Tachycardia-Induced Cardiomyopathy,” J of Cardiac Fail, 2014; 20 (8):S88-S89.

  116. Salehi et al, “Experience with Wearable Cardioverter-Defibrillator in Non-ischemic Cardiomyopathy: a National Database Analysis,” J Am Coll Cardiol, November 2, 63:12S.

  117. Bianco et al, “Survivors of Sudden Cardiac Arrest in the Presence of myocardial Infarction: Secondary Prevention with the Wearable Cardioverter Defibrillator,” J Am Coll Cardiol, 2014, 63:12S.

  118. Wickenbrock et al, “Ventricular tachycardia in post-infarction patients and coronary heart disease: treatment and prognostic significance,” Herzschr Elektrophys, 2014, 25:47-52. (in German).

  119. Bowers et al, “Use of external defibrillator jacket to facilitate safe delivery of radiotherapy for lung cancer - A report of two cases,” Indian Heart J . 2014, Jan-Feb, 66(1):111-4.

  120. Frances et al, “Wearable cardioverter defibrillator: A life vest till the lifeboat (ICD) arrives,” Indian Heart J . 2014, 2014, 66:68-72.

  121. Stollberger et al, “Wearable Cardioverter-Defibrillator in a Patient with Left Ventricular Noncompaction/Hypertrabeculation, Coronary Artery Disease, and Polyneuropathy,” Ann Noninvasive Electrocardiol, 2014, 00(0):1-3.

  122. Liang et al, “Temporal Evolution and Implications of Ventricular Arrhythmias Associated with Acute Myocardial Infarction,” Cardiol Review, 2013, 21:289-294.

  123. Wan et al, “Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator,” Ann Noninvasive Electrocardiol. 2013, November 2, [Epub ahead of print].

  124. Wan et al, “Successful use of wearable cardioverter defibrillator in a patient with dextrocardia and persistent left superior vena cava,” Ann Noninvasive Electrocardiol, 2013, Epub 2013 May 3, Sep;18(5):487-90.

  125. Nascimento et al, “Wearable cardioverter defibrillator in stress cardiomyopathy and cardiac arrest,” BMJ Case Rep, September 2013.

  126. Möller et al, “Pacemaker dependent and/or repetitive ICD therapies. How to solve the dilemma of lead extraction?,” Herzschrittmacherther Elektrophysiol, 2013, 24(3):152-7. (in German).

  127. Wan et al, “The impact of body mass index on wearable cardioverter defibrillator efficacy,” Euro Heart J, 2013, 34(suppl 1): S903.

  128. Bianco et al, “Utility of wearable cardioverter defibrillators in European patients early after myocardial infarction,” Euro Heart J, 2013, 34(suppl 1): S244.

  129. Epstein et al, “Wearable Cardioverter-Defibrillator Use in Patients Perceived to be at High Risk Early Post Myocardial Infarction,” J Am Coll Cardiol, 2013 Jul 20, [Epub ahead of print].

  130. Strauss et al, “A patient with severely reduced LV function and electrical storm saved by wearable cardioverter-defibrillator: a case report,” Herzschrittmacherther Elektrophysiol, 2013, 24(2):136-8.

  131. Bianco et al, “Compliance with wearable cardioverter-defibrillator use in a European cohort of patients,” Europace, 2013, 15(suppl 2):ii260.

  132. Wan et al, “Risk of sudden cardiac arrest in patients with myocarditis and the use of wearable cardioverter defibrillator: a German experience,” Europace, 2013, 15(suppl 2):ii117.

  133. Klein et al, “Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator,” Eur Heart J, 2013, 34(29):2230-42. Epub 2013 May 31.

  134. Bianco et al, “Wearable Cardioverter Defibrillator Use in Patients with Chemotherapy-Induced Cardiotoxicity,” Eur J Heart Fail, 2013, 12(suppl 1):S324.

  135. Shin et al, “Lifesaving events in patients protected by a wearable cardioverter-defibrillator: A single center experience,” DGK, 2013.

  136. Sperzek et al, “Role Of The Defibrillator Vest As Bridging Therapy Before ICD (Implantable Cardioverter/Defibrillator) Implantation,” Heart Rhythm, 2013, 10(5):S72.

  137. Floor et al, “The use of Wearable Cardioverter Defibrillator among high risk cardiac patients,” Heart Rhythm, 2013, 10(5):S105.

  138. Floor et al, “The use of Wearable Cardioverter Defibrillator among high risk cardiac patients,” Heart Rhythm, 2013, 10(5):S105.

  139. Styperek, R., “Preventing Sudden Cardiac Death Following Coronary Artery Bypass Graft,” EP Lab Digest, August 2013, 16-18.

  140. Goldenberg et al, “Eighteen Month Results From The Prospective Registry And Follow-up Of Patients Using The Lifevest Wearable Defibrillator (WEARIT-II Registry),” Heart Rhythm Society, 2013, Late Breaking Clinical Trial.

  141. Deeprasertkul et al, “National Experience with Wearable Cardioverter-Defibrillator Use in Takotsubo Cardiomyopathy,” Journal of the American College of Cardiology, 2013, 61 (S10).

  142. Adler et al, “Wearable cardioverter-defibrillators,” Circulation, 2013, 127(7):854-60.

  143. Norman and Collier, “A Collaborative Approach to Managing Sudden Cardiac Death Risk,” Diagnostic and Interventional Cardiology, March/April 2013, 24-25.

  144. Zishiri et al, “Early Risk of Mortality after Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator,” Circulation: Arrhythmia and Electrophysiology, February 2013, 117-128.

  145. Kao et al, “Wearable defibrillator use in heart failure (WIF): results of a prospective registry,” BioMed Central Cardiovascular Disorders, 2012, 12(1):123.

  146. Karia et al, “Baseline ECG Predictors of 90-Day Survival in Wearable Cardioverter-Defibrillator Patients Experiencing a Sudden Cardiac Arrest,” Circulation, 2012, 126:A186.

  147. Karia et al, “Dynamic ECG Changes in Wearable Cardioverter Defibrillator Patients Predict Impending Sudden Cardiac Arrest,” Circulation, 2012, 126:A8.

  148. Wan et al, “Patients with Terminal Illness Using a Wearable Cardioverter Defibrillator,” Circulation, 2012, 126:A75.

  149. Horstmanshof et al, “Experience with the Wearable Cardioverter Defibrillator in Heart Transplant Candidates,” Journal of Cardiac Failure, 2012, 18(10 suppl):S49-S50.

  150. Wan et al, “Use of Wearable Cardioverter Defibrillator after Implantable Cardioverter Defibrillator explantation: Clinical Experience from 151 German centers,” European Heart Journal, 2012, 33(suppl 1):Sxxx.

  151. Wan et al, “Physical Activity and Relation to Sudden Cardiac Arrest,” Europace, 2012, 14(suppl 1):i122.

  152. Levine, J., “Sudden Cardiac Arrest in a Young AMI Patient Following Percutaneous Revascularization,” CardioSource Interventional News, July/August 2012, 18-20.

  153. Goodfellow, R., “Preventing Sudden Cardiac Death Following Percutaneous Revascularization,” Cath Lab Digest, June 2012, 16-18.

  154. Szymkiewicz et al, “ECG Quality of Dry, Non-adhesive Electrodes for Arrhythmia Monitoring [Abstract],” Europace, 2012, 14(suppl 1):i1.

  155. Wan et al, “Physical Activity and Relation to Sudden Cardiac Arrest [Abstract],” Europace, 2012, 14(suppl 1):i122.

  156. Bianco et al, “Protecting the Alcoholic Cardiomyopathy Patient: Bridge to Decision with the Wearable Cardioverter Defibrillator [Abstract],” European Journal of Heart Failure, 2012, 11(suppl 1):S21.

  157. Glad et al, “Do multiple shock episodes impact survival outcomes in patients with a Wearable Cardioverter Defibrillator? [Abstract],” Heart Rhythm, 2012, 9(5):S446.

  158. Peters et al, “WCD LifeVest: risk stratification in a case of Tako-Tsubo cardiomyopathy with QT interval prolongation,” Herz, 2012, 37(2):219-21.

  159. Whiting, J., Simon, M., “Health and Lifestyle Benefits Resulting from Wearable Cardioverter Defibrillator Use,” The Journal of Innovations in Cardiac Rhythm Management, March 2012, 1-2.

  160. Epstein et al, “Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-MI [Abstract],” Journal of the American College of Cardiology, 2012, 59:E644.

  161. Wan et al, “Improved sudden cardiac arrest survival in hemodialysis patients with wearable cardioverter-defibrillator [Abstract],” Journal of the American College of Cardiology, 2012, 59:E651.

  162. Mirro, M., “Use of the Wearable Automatic Defibrillator: Outcomes and Compliance [Abstract],” Heart Rhythm, 2011, 8 (S5):S435.

  163. Knops et al, “First experience with the wearable cardioverter defibrillator in the Netherlands,” Netherlands Heart Journal, 2012, 20(2):77-81.

  164. Saltzberg et al, “Characteristics and Outcomes of Peripartum versus Non-peripartum Cardiomyopathy in Women using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2012, 18:21-27.

  165. Zishiri et al, “Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction [Abstract],” Circulation, 2011, 124:A9816.

  166. Cronin et al, “Some Like It Cool - Seasonal Temperature, as Well as Clinical And Demographic Factors, Predicts Compliance With the Wearable Cardioverter Defibrillator [Abstract],” Circulation, 2011, 124:A14183.

  167. Mosesso et al, “Successful conversion of Ventricular arrhythmias by a Wearable Defibrillator [Abstract],” Circulation, 2011, 124:A278.

  168. Wan et al, “Economic Evaluation of the Wearable Cardioverter-Defibrillator in Patients After ICD Explantation [Abstract],” Circulation, 2011, 124:A245.

  169. Wan et al, “The Wearable Cardioverter Defibrillator Is Cost-Effective in Protecting High-Risk Patients After Acute Myocardial Infarction [Abstract],” Circulation, 2011, 124:A100.

  170. Dewland et al, “Indications for Wearable Cardioverter Defibrillator,” Cardiac Electrophysiology Clinics, 2011, 3(2001), 339-347.

  171. Austin et al, “Frequency of Improvement in Ventricular Function Allows Many Patients to Defer Defibrillator Implantation,” Journal of Cardiac Failure, 2011, 17(8): S102.

  172. Bianco et al, “Extending Wearable Cardiac Defibrillator Use in Heart Failure Patients beyond the ICD waiting period,” Journal of Cardiac Failure, 2011, 17(8): S52.

  173. Everitt et al, “The Wearable External Cardiac Defibrillator for cancer patients at risk for sudden cardiac death,” Community Oncology, 2011, 8(9): 400-403.

  174. Mohan Rao et al, “Wearable defibrillator in Congenital Structural Heart Disease and Inherited Arrhythmias: A Multicenter Experience,” Journal of Cardiovascular Electrophysiology, 2011, In press.

  175. Saltzberg et al, “Characteristics and Outcomes of Peripartum versus Non-peripartum Cardiomyopathy in Women using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2011, In press.

  176. Glad et al, “Protecting Tako tsubo patients from sudden death: Are wearable defibrillators the answer,” Journal of Cardiac Failure, Vol 17, Issue 8, Supplement 1, Page S55.

  177. Wan et al, “Incidence of Inappropriate Wearable Defibrillator Shocks is Rare: An Evaluation fo 15,193 Wearable Defibrillator Patients,” Europace, 2011, 13(3): 375.

  178. Saltzberg et al, “Use of a Wearable Cardioverter Defibrillator among Pre-partum Pregnant Women: An analysis of Safety, Characteristics and Outcomes,” European Journal of Heart Failure, 2011, 10(suppl 1):S26.

  179. Karia et al, “Rate of LV Systolic Function Recovery in Cardiomyopathy Patients Prescribed Wearable Cardiac Defibrillator,” European Heart Failure Congress, 2011.

  180. Glad et al, “Survival outcomes for post shock asystole in patients wearing a WCD,” Europace, 2011, 13(3): 1203.

  181. Glad et al, “Sudden cardiac arrest survival in patients wearing a wearable cardiac defibrillator: Geographic location does not impact survival,” Europace, 2011, 13(3): 1204.

  182. Bianco et al, “Long-Term Mortality Risk in Post-Myocardial Infarct Patients Resuscitated by a Wearable Cardiac Defibrillator,” Journal of the American College of Cardiology, April 5, 2011, 57: E39.

  183. Carillo, R., “Wearable Defibrillator in Patients Following ICD Explants for Sudden Cardiac Death Protection [Abstract],” Heart Rhythm, 2011, 8(5S): S435.

  184. Hanson, R. et al, “Clinical Outcomes among Patients Using a Wearable Defibrillator,” Journal of the American College of Cardiology, April 5, 2011, 57: E1128.

  185. Rao, M. et al, “Wearable Defibrillator in Congenital Heart Disease and Inherited Arrhythmia: A Multicenter Experience,” Journal of the American College of Cardiology, April 5, 2011, 57: E467.

  186. Deering et al, “Wearable Defibrillator Use After Myocardial Infarction: Results of the WAMI Registry,” JACC, 2011, 57:A14.

  187. Conti, “External Defibrillator, Life Vest Wearable Defibrillator, or Both?,” Clin Cardiol, 2010, 33(12):722-3.

  188. Glad et al, “Early Defibrillation in Patients Wearing a Wearable Defibrillator,” Circulation, 2010, 12(2):120.

  189. Bianco et al, “Wearable Defibrillators Within a NYHA Class IV Heart Failure Population,” Journal of Cardiac Failure, 2010, 16(8):S57.

  190. Verdino, “The Wearable Cardioverter-Defibrillator: Lifesaving Attire or "Fashion Faux Pas?,” JACC, 2010, 56:204-205.

  191. Chung et al, “Aggregate national experience with the wearable cardioverter-defibrillator vest: event rates, compliance and survival,” JACC, 2010, 56:194-203.

  192. Bianco et al, “The Impact of Age on Wearable Cardioverter-Defibrillator Compliance and Treatment,” Europace, 2010, 12(1 suppl):i158.

  193. Bianco et al, “Impact of transthoracic impedance on wearable cardioverter-defibrillator effectiveness,” Europace, 2010, 12(1 suppl):i53.

  194. Karia et al, “Newly Diagnosed Non-ischemic Cardiomyopathy patients bridged with the Wearable Cardioverter Defibrillator,” Eur J Heart Failure, 2010, 9 (suppl 1):S149.

  195. Mitrani et al, “Use of Automatic Wearable Defibrillator in an Uninsured Patient Population,” Heart Rhythm, 2010, 7(5 suppl):S234.

  196. Carrillo et al, “Wearable defibrillator use after ICD explantation,” Heart Rhythm, 2010, 7(5 suppl):S437.

  197. Bianco et al, “Impact of transthoracic impedance on wearable cardioverter-defibrillator effectiveness,” Heart Rhythm, 2010, 7(5 suppl):S365.

  198. Zishiri, et al, “Appropriateness of ICD indications: insights from an analysis of mortality rates in patients using a wearable cardioverter-defibrillator,” Heart Rhythm, 2010, 7(5 suppl):S122.

  199. Szymkiewicz et al, “Wearable defibrillator use prior to ICD implantation or evaluation,” Heart Rhythm, 2010, 7(5 suppl):S54.

  200. Chung et al., “Aggregate national experience with the wearable cardioverter-defibrillator vest: event rates, compliance and survival,” JACC, 2010, 55(10 suppl 1):A10.

  201. Everitt et al., “Use of the Wearable External Cardiac Defibrillator in Children,” PACE, 2010 Feb 23., [Epub ahead of print].

  202. Klein et al., “The Wearable Cardioverter Defibrillator: Bridge to the Implantable Defibrillator,” Cardiac Electrophysiology Clinics, 2009, 2009;1(1):129-46.

  203. Zareba et al., “Sudden Cardiac Arrest in End-Stage Renal Disease: Successful Resuscitation With Wearable Cardiac Defibrillator,” Circulation, Nov 2009, 120: S701 - S702.

  204. Prochnau, “Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction,” Clin Res Cardiol, 2009 Nov 17., [Epub ahead of print].

  205. Klein et al., “Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD),” PACE, 2009 Nov 2, [Epub ahead of print].

  206. Lee et al., “Role of wearable and automatic external defibrillators in improving survival in patients at risk for sudden cardiac death,” Curr Treat Options Cardiovasc Med, 2009, 11(5):360-5.

  207. Saltzberg et al., “Characteristics of Peripartum Cardiomyopathy Patients Using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2009, 15(6):S59.

  208. Dillon et al., “An evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm,” Journal of Electrocardiology, 2009 June, (electronic ahead of print).

  209. Morrison et al., “Taking a vested interest in a wearable cardioverter defibrillator,” Nursing, 2009, 39(6):30-2.

  210. Szymkiewicz, et al., “Incidence and causes of inappropriate defibrillation during wearable defibrillator use,” Heart Rhythm, 2009, 6(5): S74.

  211. Lewicke et al., “Exploring QT interval changes as a precursor to the onset of ventricular fibrillation/tachycardia,” Journal of Electrocardiology, 2009, 42(4):374-9.

  212. Szymkiewicz, et al., “A Comparison of Compliance and Effectiveness of Wearable Defibrillators and Home AEDs in Out-of-Hospital Sudden Cardiac Arrest,” Circulation, 2008, 118: S_1466.

  213. Mortada et al., ““Sudden Cardiac Death” in: Jeremias A, Brown DL (eds),” Cardiac Intensive Care, 2nd Edition, Elsevier, St. Louis (in press).

  214. Abi-Samra et al., “Wearable Defibrillator: Effective Bridging Substitute for ICD Implants,” Europace, 2008, 10: i160.

  215. Freeman et al., “Is Severe Post-shock Bradyarrhythmia In Patients Using Wearable Defibrillators Common or Serious?,” Circulation, 2007, 116: II_931.

  216. Wang et al., “Ventricular Fibrillation remains the Primary Presenting Rhythm: Results from the Wearable Cardioverter Defibrillator Human Study,” Circulation, 2007, 116: II_934 - II_935.

  217. Choudhuri et al., “Arrhythmic Events During the 40/90 days ‘Cooling Off’ Period: Clinical Utility of the Wearable Defibrillator,” Circulation, 2007, 116: II_348.

  218. Traub et al., “Sudden cardiac arrest aborted by a wearable cardioverter-defibrillator in newly diagnosed non-ischemic cardiomyopathy,” Heart Rhythm, 2007, 4(5, suppl):S101.

  219. Losordo et al., “Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina: A Phase I/IIa Double-Blind, Randomized Controlled Trial,” Circulation, 2007, 115:3165 - 3172.

  220. Gronda et al., “Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates?006,” J Heart Lung Transplant, 2006, 25(9):1043-1056.

  221. Szymkiewicz et al., “Analysis of Sudden Cardiac Arrests During Wearable Defibrillator Use,” Circulation, 114 (18, suppl II):II-349, 2006.

  222. Wase, “Wearable Defibrillators: A New Tool in the Management of Ventricular Tachycardia/Ventricular Fibrillation,” EP Lab Digest, 2005, 12:22-24.

  223. Meltendorf, “Using the Wearable Cardioverter Defibrillator a strategy for bridging high risk patients after CABG,” Heart Rhythm, 2005, 2(5, suppl):S32.

  224. Joseph et al., “Compliance and Effectiveness of the Wearable Defibrillator Vest,” JACC, 2004, 43(5, suppl A):300A.

  225. Chung et al., “Robust Long-Term Cardiac Monitoring Using Dry, Non-adhesive Capacitive Electrodes,” JACC, 2004, 43(5, suppl A):141A.

  226. Feldman et al., “Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death: Results of WEARIT/BIROAD,” PACE, 2004, 27:4-9.

  227. Beauregard, “Personal Security: Clinical Applications of the Wearable Defibrillator,” PACE, 2004, 27(1):2-3.

  228. Reek et al., “Clinical Efficacy of a Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks,” PACE, 2003, 26:2016-2022.

  229. Suzzani P et al., “The lifecor lifevest™ wearable cardioverter defibrillator,” Europace, 2003, 4(Supplement 1):A46.

  230. Pignatelli et al., “Use of a new wearable cardioverter defibrillator to reduce the risk of sudden cardiac death,” Europace, 2003, 4(Supplement 1):A45-A46.

  231. Gasparini et al., “A new wearable defibrillator: Initial single center experience,” Europace, 2003, 4(Supplement 1):A45.

  232. Capucci et al., “Cost-effective use of a new wearable cardioverter defibrillator to protect patients at risk of SCA,” Europace, 2003, 4(Supplement 1):A44-A45.

  233. Reek et al., “Clinical Efficacy of the Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks,” PACE, 2003, 25(4, part II):577.

  234. Reek et al., “A wearable defibrillator for patients with an intermittent risk of arrhythmia,” Dtsch Med Wochenschr, 2002, 127(41):2127-30.

  235. Schott, “The Wearable Defibrillator,” J Cardiovasc Nurs, 2002, 16(3):44-52.

  236. Reek et al., “The Wearable Cardioverter Defibrillator (WCD®) for the prevention of sudden cardiac death? a single center experience,” Z Kardiol, 2002, 91:1044?052.

  237. Meltendorf et al., “The Wearable Defibrillator? A new Method to prevent Sudden Death,” PACE, 2000, 23(4, part II):606.

  238. Auricchio et al., “Clinical Efficacy of the Wearable Cardioverter-Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation,” Am J Card, 1998, 81(10):1253-1256.